Shan Zhao, Shuo Kang. "Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer." Scientific Reports (2025). https://doi.org/10.1038/s41598-025-29534-w